Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
The presentation, titled, "Human microRNAs: Powerful Biomarkers forCancer Diagnostics", is part of a plenary session on the molecularclassification of tumors, which will be held on Wednesday, September 19,between 10:45 am-1:00 pm.
An audio webcast of the presentation will be made available by AACR 15days after the conference at the following url:http://www.aacr.org/home/scientists/meetings--workshops/molecular-diagnostics-in-cancer-therapeutic-development.aspx
(Due to the length of this URL, it may be necessary to copy and pastethis hyperlink into your Internet browser's URL address field. Remove thespace if one exists.)
About Rosetta Genomics
Rosetta Genomics (Nasdaq:ROSG) is a leader in the development ofmicroRNA-based diagnostics and therapeutics. Founded in 2000, the company'sintegrative research platform combining bioinformatics and state-of-the-artlaboratory processes has led to the discovery of hundreds of biologicallyvalidated novel human microRNAs. Building on its strong IP position andstrategic alliances with leading biotechnology companies, Rosetta Genomics isworking to develop a full range of diagnostic and therapeutic products basedon microRNAs. The company's primary focus is in the development ofmicroRNA-based products to diagnose and treat different forms of cancer andvarious diseases. For more information please visit:http://www.rosettagenomics.comContact: Media Alan Zachary T: +1-312-944-6784 firstname.lastname@example.org Investors Juliane Snowden T: +1-212-213-0006 email@example.com
SOURCE Rosetta Genomics Ltd
You May Also Like